Pregunta del mes | Kern Pharma Biologics

BRAF-MEK inhibition in melanoma brain metastases: a new hope

0
0 / 5 (0 votos)

The Lancet Oncology
Published
: July 2017
DOI: http://dx.doi.org/10.1016/S1470-2045(17)30449-7

Peter A Forsyth, Keiran S M Smalley, Vernon K Sondak

About 30% of patients with stage IV melanoma manifest clinically apparent melanoma brain metastasis at some point in their disease course. Until about 5 years ago, few patients with melanoma brain metastasis were eligible for clinical trials, and survival rates were dismal. The development of brain metastases is a complex process that involves tumour cells escaping from the primary or other metastatic sites, intravasating into the systemic circulation, and arresting in and extravasating from intracranial capillary beds, ultimately resulting in the establishment…

Seguir leyendo